Your genetic make up (your DNA) provides a crucial role in how your body responds to medication.
Pharmacogenomic (PGx) DNA testing empowers you and your healthcare provider to develop a tailored treatment plan for maximum effectiveness.
Taken medications in the past and found them not to work?
Pharmacogenomic Testing (PGx) of your DNA may be able to help
Depending on your unique genetic makeup, you may process a medication:
This is because we all process medications differently.
If we are all given the same medication at the same dose, we react in four different ways:
By testing our DNA, we can work out how we may react to each medication.
Thus testing can help your doctor determine the right medication at the right dose for you.
Pharmacogenomic testing is a powerful tool that empowers both you and your doctor to make informed, personalized decisions about your medication, helping you achieve better health outcomes quickly and safely.
Talk to your doctor about your options, and request an PGx test.
Visit one of our collection centres to get your sample collected.
Your doctor will discuss any relevant findings and advise genetic counselling if necessary.
Efficacy of medication is not solely dependent on your DNA. Other factors will impact whether a medication is effective or not and at what dose, including general health, environmental factors, or other medications.
Your DNA test results are like a permanent record of your genetic makeup. They won’t change over time. This means even if you don’t need medication now, these results can be valuable in the future. If you’re considering taking a new medication in future, you can revisit these results with your healthcare provider to determine the best course of action.
At least 70% of people who have taken a Pharmacogenomic test have a finding that could affect current or future medications.
We will send your doctor your report in about 2 weeks from the date of sample collection. Please ask them to share a copy of the report with you.
Genomic Diagnostics has a partnership with myDNA, Inc to undertake PGx Multi testing. Your sample and request will be sent to the myDNA accredited laboratory in Melbourne, Australia for testing. As such, patient samples and associated personal and health information will be securely transferred and processed in accordance with local privacy laws.
Pharmacogenomics is the study of the role that DNA variants play in drug efficacy. The DNA variants may either be inherited, and part of an individual’s inherited genetic make-up, or may be acquired in a person’s tumour (non-heritable) and can be used to predict drug responses or the likelihood of adverse drug reactions.
In addition to specific tests available for the enzymes thiopurine S-methyltransferase (TPMT) and glucuronyltransferase (UGT1A1), the Pharmacogenomic (PGx) Multi panel covers enzymes involved in breaking down medications used in the mental health area and the pain area as well as a wide range of other medications.
In the case of cancer treatment, the mutations acquired in a person’s tumour (non-heritable) may make the tumour more sensitive or resistant to treatment targeted gene, or gene pathway, specific treatment.
Providing the patient with the right dose of the right medicine is the aim of personalised medicine. Variation in an individual’s genetic makeup compared to others in the general population can affect their response to medications because some of these variations affect drug metabolic pathways. In some cases, this may result in sub-optimal therapeutic levels, or conversely, toxic adverse effects.
The PGx Multi test analyses variations in genes that have been shown to influence drug response and metabolism for over 100 medications used commonly in clinical practice including medications used in mental health, pain, cardiology, gastroenterology and more.
The report provides medication-specific prescribing considerations to help improve the safety and efficacy of medications and reduce the risk of unwanted side effects.
PGx Multi
To determine optimal medication and dosage for multiple pharmaceutical agents
CYP2D6*2, *3, *4, *5, *6, *7, *8, *9, *10, *14A, *14B, *17, *29, *36, *41; CYP2C19*2, *3, *17; CYP2C9*2, *3; CYP1A2*1F; CYP3A4*22; CYP3A5*3; SLCOB1, VKORC1, OPRM1, ABCG2 and CYPB26
PCR Genotyping
2 weeks from sample receipt
No
$197
Standard pathology request form
6mL EDTA tube
Please specify the medications of interest on the request form
Thiopurine drugs are used as both immunosuppressive and chemotherapeutic agents. Inherited genetic variants that result in reduced activity of the enzyme thiopurine S-methyltransferase (TPMT) are associated with cytoxicity and particularly with bone marrow failure. Multiple variants have been associated with decreased TPMT activity but 4 specific variant alleles (TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C), account for the majority (>95%) of low and intermediate activity cases. Patients with one variant allele have intermediate activity whereas those with two variants have low or no activity. TPMT genetic testing can predict thiopurine drug toxicity in a variety of conditions, including renal transplantation, rheumatoid disease, inflammatory bowel disease and lymphoblastic leukaemia. Genetic variants have also been implicated in ototoxicity associated with specific drug treatment in children.
TPMT genotype
TPMT
PCR Genotyping
7 days
If not MBS eligible, please contact 1800 822 999 for pricing details
Standard pathology request form
Blood
6mL EDTA Tube
None
Gilbert’s syndrome is characterised by jaundice due to increased levels of unconjugated plasma bilirubin. Men are at higher risk than females and usually present post-puberty. In people of northern European ancestry, cases of Gilbert’s syndrome are often associated with inheriting two copies (one from each parent) of a specific mutation in the promoter region of the gene encoding the enzyme glucuronyltransferase (UGT1A1), designated UGT1A1*28 allele. UGT1A1 is a liver enzyme important for clearing conjugated bilirubin from the circulation. In general, other than the low grade elevated bilirubin levels, people with Gilbert’s syndrome exhibit no other signs or symptoms. In some cases, toxicity therapeutic agents, such as specific anticancer agents and anti-viral protease inhibitors, may occur in patients with Gilbert’s syndrome. Testing for Gilbert’s syndrome may assist in differentiating the cause of isolated elevated bilirubin levels in those patients with normal test results for FBC, reticulocytes, haptoglobin and liver enzymes.
Gilbert’s Syndrome Genotyping
UGT1A1 (UDP-glucuronosyltransferase Family 1 Member A1)
PCR Genotyping
28 days
No
$200
Standard pathology request form
Blood
6mL EDTA tube
None
Talk to your GP about your options, and request an Pharmacogenomics test.
Visit one of our collection centres to get your sample collected.
Your doctor will discuss any relevant findings and advise genetic counselling if necessary.
Test results for the PGx Multi are downloaded into your practice management software in the usual manner.
There is two reports, a summary report and a detailed pdf report. The latter pdf report contains additional information on prescribing for the patient, based on international guidelines.
If you are not receiving this additional pdf report please let us know on 1800 822 999.
The PGx Multi is a non-Medicare rebateable test. Please ask your patients to pay via the shopping cart on this website or or call 1800 822 999 before having their bloods collected.
Simply request PGx Multi on a standard request form. It is important to list all medications the patient is currently taking, so an accurate report can be returned.